This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Pionyr Immunotherapeutics, Inc., University of California. Active years: 2022-2026.
Company Filing History:
Years Active: 2022-2026
Title: Mikhail Binnewies: Innovator in Immunotherapy
Introduction
Mikhail Binnewies is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of immunotherapy, particularly through his innovative research and patents. With a total of 2 patents, his work focuses on enhancing immune responses to combat various conditions, including cancer.
Latest Patents
One of Mikhail's latest patents is titled "Methods of Using Anti-TREM2 Antibodies." This patent outlines methods and compositions for enhancing an immune response and treating immune-related conditions in individuals. The approach involves killing, disabling, or depleting non-stimulatory myeloid cells using an antigen binding protein, such as an antibody or its fragments. This innovative method has the potential to significantly impact cancer treatment.
Career Highlights
Mikhail has worked with esteemed organizations, including the University of California and Pionyr Immunotherapeutics, Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in immunotherapy.
Collaborations
Mikhail has collaborated with notable colleagues, including Miranda Broz and Matthew F Krummel. These partnerships have further enriched his research and have led to advancements in understanding immune responses.
Conclusion
Mikhail Binnewies is a key figure in the field of immunotherapy, with a focus on innovative methods to enhance immune responses. His contributions through patents and collaborations continue to pave the way for advancements in cancer treatment and immune-related conditions.